What Takeda Oncology does

Takeda Oncology is the Global Oncology Business Unit of Takeda Pharmaceutical Company Limited (NYSE:TAK, TSE:4502), headquartered at 40 Landsdowne Street in Cambridge, Massachusetts. The unit develops and commercializes prescription pharmaceuticals for three priority disease areas: hematologic cancers (lymphoma, leukemia, multiple myeloma, polycythemia vera), thoracic cancers (non-small cell lung cancer, including ALK-positive and EGFR mutation subsets), and gastrointestinal cancers (metastatic colorectal cancer). Its approved portfolio of seven marketed medicines spans multiple therapeutic modalities — small-molecule kinase inhibitors (brigatinib/ALUNBRIG, ponatinib/ICLUSIG, fruquintinib/FRUZAQLA, mobocertinib/EXKIVITY), antibody-drug conjugates (brentuximab vedotin/ADCETRIS), proteasome inhibitors (bortezomib/VELCADE, ixazomib/NINLARO) — and a pipeline anchored by rusfertide, a first-in-class hepcidin mimetic peptide for polycythemia vera currently under FDA Priority Review with a PDUFA goal date in Q3 2026.

The company pursues a global enterprise field-sales and co-commercialization model, distributing approved medicines through specialty pharmacies, hospital systems, and oncology clinic networks across approximately 80 countries, with field medical representatives engaging oncologists, hematologists, and thoracic oncologists. Revenue is generated primarily through prescription pharmaceutical product sales under government reimbursement, insurance, and patient assistance programs; oncology treatment costs for newer drugs range from $10,000-$30,000 per month. Pipeline revenue is augmented by licensing and royalty streams, including a January 2024 collaboration with Protagonist Therapeutics for rusfertide (up to $400M in opt-out payments plus 14-29% tiered royalties on worldwide net sales) and a partnership with Innovent for TAK-928 (IBI363), an IL-23R-targeted therapy in NSCLC.

Takeda Oncology's competitive position rests on a combination of regulatory exclusivity (Breakthrough Therapy, Orphan Drug, and Fast Track designations for rusfertide), proprietary chemistry across multiple modalities, and the global distribution scale of its Takeda parent — the oncology franchise traces back to the 2008 acquisition of Millennium Pharmaceuticals. Recent strategic activity has been pipeline-heavy: rusfertide NDA submission in January 2026, FDA Priority Review granted in March 2026, ASCO 2026 data presentations across all three priority disease areas, and ongoing integration of two 2024 in-licensing deals. The unit is led by Teresa Bitetti (President, Global Oncology Business Unit), Dr. P.K. Morrow (Head, Oncology Therapeutic Area Unit), and Dr. Andy Plump (President of R&D at Takeda).

Name

Takeda Oncology

Legal name

Takeda Pharmaceutical Company Limited

Website

https://takedaoncology.com

Company type

Public

Founded year

1781

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Takeda Oncology is the Global Oncology Business Unit of Takeda Pharmaceutical, developing and commercializing prescription medicines across hematologic, thoracic, and gastrointestinal cancers across approximately 80 countries.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Medical Oncology (HLAKAFAB), Gastrointestinal Oncology (HLAKAFAK)

Keywords

• Oncology pharmaceuticals
• Cancer therapeutics
• Kinase inhibitors
• Antibody drug conjugates
• Hematologic oncology

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain, Infrastructure

Revenue model

1. Oncology pharmaceutical product sales: Takeda Oncology generates revenue through the global sales of its approved oncology medicines including ALUNBRIG (brigatinib), ADCETRIS (brentuximab vedotin), EXKIVITY (mobocertinib), FRUZAQLA (fruquintinib), ICLUSIG (ponatinib), NINLARO (ixazomib), and VELCADE (bortezomib). These are distributed to hospitals, specialty pharmacies, and oncology clinics worldwide.
2. Co-development and co-commercialization milestone payments (rusfertide): Under its January 2024 worldwide license and collaboration agreement with Protagonist Therapeutics, Takeda and Protagonist co-develop and will co-commercialize rusfertide. Protagonist can opt to co-commercialize in the U.S. via a 50/50 profit and loss share structure or opt out, in which case Takeda receives a worldwide license. Takeda receives milestone payments and royalty streams from the partnership.
3. TAK-928 / IBI363 global co-development: Takeda entered a license and collaboration agreement with Innovent for TAK-928 (IBI363), where Takeda leads global co-development and U.S. co-commercialization and holds exclusive commercialization rights outside the U.S. and Greater China.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

Core offering

Takeda Oncology develops, manufactures, and commercializes prescription pharmaceuticals for the treatment of cancer, operating as the Global Oncology Business Unit of Takeda Pharmaceutical Company Limited. Its portfolio includes approved oncology medicines (ALUNBRIG, ADCETRIS, EXKIVITY, FRUZAQLA, ICLUSIG, NINLARO, VELCADE) spanning hematologic, thoracic, and gastrointestinal cancers, plus a pipeline of investigational therapies including rusfertide for polycythemia vera and TAK-928 for NSCLC. The business distributes these medicines through specialty pharmacies, hospitals, and oncology clinics across roughly 80 countries, supplemented by co-development and licensing partnerships.

Product overview

Takeda Oncology is a pharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company's product portfolio includes approved medicines for hematologic cancers (lymphoma, leukemia, multiple myeloma), thoracic cancers (non-small cell lung cancer), and gastrointestinal cancers (colorectal cancer). The approved product portfolio includes ALUNBRIG (brigatinib), FRUZAQLA (fruquintinib), ADCETRIS, EXKIVITY, ICLUSIG, NINLARO, and VELCADE. The pipeline includes investigational medicines such as rusfertide (hepcidin mimetic for polycythemia vera), which is under FDA Priority Review with PDUFA date in Q3 2026, and TAK-928 (for NSCLC) in partnership with Innovent. The company focuses on three priority disease areas: hematologic cancers, thoracic cancers, and gastrointestinal cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• ALUNBRIG (brigatinib) A kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), positioned as a targeted therapy for the ALK-positive NSCLC subsegment.
• ADCETRIS (brentuximab vedotin) An antibody-drug conjugate (ADC) targeted therapy for the treatment of certain lymphomas, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
• EXKIVITY (mobocertinib) A tyrosine kinase inhibitor medicine for the treatment of certain cancers, specifically EGFR Exon20 insertion+ NSCLC.
• FRUZAQLA (fruquintinib) A small-molecule VEGFR inhibitor indicated for treatment of adult patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and (if RAS wild-type and medically appropriate) an anti-EGFR therapy.
• ICLUSIG (ponatinib) A BCR::ABL tyrosine kinase inhibitor indicated for the treatment of certain leukemias, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in patients resistant or intolerant to prior TKI therapy.
• NINLARO (ixazomib) An oral proteasome inhibitor for the treatment of multiple myeloma.
• VELCADE (bortezomib) A proteasome inhibitor for the treatment of multiple myeloma and mantle cell lymphoma.
• Rusfertide (investigational) First-in-class hepcidin mimetic peptide therapy administered once weekly via subcutaneous self-injection, designed to regulate iron homeostasis and red blood cell production to control hematocrit in adult patients with polycythemia vera. Co-developed with Protagonist Therapeutics under a worldwide license and collaboration agreement.
• TAK-928 / IBI363 (investigational) Investigational interleukin-23 receptor (IL-23R) targeted therapy for non-small cell lung cancer (NSCLC), being studied in immunotherapy-resistant and previously untreated NSCLC. Takeda leads global co-development and U.S. co-commercialization and holds exclusive commercialization rights outside the U.S. and Greater China.

Quantifiable outcome

• 61.9% of patients treated with rusfertide maintained absence of phlebotomy eligibility from baseline to Week 52 in the Phase 3 VERIFY study (NCT05210790)
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Protagonist TherapeuticscoreStrategic or Co-development Partner · 1 January 2024Takeda entered a worldwide license and collaboration agreement with Protagonist Therapeutics in January 2024 for rusfertide, a first-in-class hepcidin mimetic for polycythemia vera. Protagonist discovered and led development through Phase 3, while Takeda implements the regulatory strategy for U.S. NDA filing and leads future global regulatory filings. The companies will co-commercialize rusfertide, with Protagonist holding an option to co-commercialize in the U.S. via a 50/50 profit and loss share or opt out for enhanced milestones (up to $400 million) and 14-29% tiered royalties on worldwide net sales. An NDA was submitted in January 2026 and accepted with Priority Review by FDA in March 2026.
• Innovent BiologicscoreStrategic or Co-development PartnerTakeda entered a license and collaboration agreement with Innovent for TAK-928 (also referred to as IBI363 by Innovent), an IL-23R targeted therapy. Takeda leads global co-development and U.S. co-commercialization of TAK-928, and holds exclusive commercialization rights outside the U.S. and Greater China. New Phase 1 data in previously untreated NSCLC is being presented at ASCO 2026.
• LUNGevity FoundationsupportingOthersTakeda Oncology collaborates with LUNGevity Foundation, one of the nation's leading lung cancer patient advocacy organizations, to improve outcomes for people with lung cancer through policy initiatives, education, support, and engagement. Areas of collaboration include advancing precision medicine, improving accessibility of comprehensive biomarker testing, transforming clinical trials to be more patient-centric, and fostering health equity and diversity and inclusion in lung cancer care.
• Leukemia and Lymphoma Society (LLS)supportingOthersTakeda Oncology partners with the Leukemia and Lymphoma Society (LLS), a leading nonprofit organization dedicated to blood cancer research, patient education, and advocacy. LLS is listed as a patient resource on Takeda's leukemia patient page, providing educational materials and support services for leukemia patients.
• The Max FoundationsupportingOthersTakeda Oncology partners with The Max Foundation, a nonprofit organization that works to improve access to treatment for leukemia and other blood cancer patients globally. The Max Foundation is listed as a patient resource on Takeda's leukemia patient page.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• AbbVie: AbbVie competes with Takeda in hematology through Imbruvica and Venclexta (CLL/lymphoma) and has comparable global commercial scale. AbbVie's hematology/oncology focus overlaps significantly with Takeda Oncology's portfolio priorities.
• Roche / Genentech: Roche is the world's largest oncology company with a broad portfolio across solid tumors and hematologic malignancies. Its anti-CD20 franchise (Rituxan, Gazyva) and Alecensa (ALK+ NSCLC) compete directly with Takeda's ADCETRIS and ALUNBRIG.
• AstraZeneca: AstraZeneca is a leading NSCLC player through Tagrisso (EGFR) and Imfinzi, competing directly with Takeda's ALUNBRIG and TAK-928 in lung cancer. Its global oncology commercial footprint and focus on precision oncology make it a comparable peer.
• Pfizer Oncology: Pfizer is a leading oncology player with a broad portfolio including lorlatinib (Lobrena) for ALK+ NSCLC that directly competes with Takeda's ALUNBRIG. Pfizer's global commercial infrastructure and oncology R&D scale make it a comparable peer across multiple indications.
• Novartis Oncology: Novartis operates a broad oncology portfolio including radioligand therapy (Pluvicto), targeted therapies, and hematology assets. As a top-3 oncology player, it competes with Takeda across multiple disease areas and has comparable global commercial scale.
• Amgen Oncology: Amgen competes in hematologic malignancies through BLINCYTO (ALL) and has a growing oncology biologics franchise. Its acquisition of Horizon Therapeutics expanded its rare disease and oncology footprint, making it comparable in scale and focus.
• Astellas Pharma: Astellas is a global oncology player with Xtandi (prostate cancer) and Padcev (urothelial cancer), and competes with Takeda in ADC development. The company has comparable global commercial scale and a similar focus on specialty oncology indications.

Direct peers

• Incyte Corporation: Incyte markets Jakavi (ruxolitinib) for polycythemia vera, the current standard of care that rusfertide would compete against. Incyte is a direct competitor in hematology and PV, with a focused commercial footprint in MPNs and graft-vs-host disease.
• Bristol-Myers Squibb: BMS is a top-tier oncology competitor directly overlapping Takeda's hematology portfolio through Revlimid, Empliciti (multiple myeloma), Sprycel (CML), and Opdivo. Both compete in lymphoma, leukemia, and multiple myeloma with global commercial infrastructure.
• Jazz Pharmaceuticals: Jazz Pharmaceuticals focuses on rare hematology and oncology through Vyxeos (AML) and Erwinaze, comparable to Takeda Oncology's focus on rare blood cancers. Both companies target specialty hematology markets with similar commercial approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

• Xx.com/TakedaOncology
• Facebookfacebook.com/takedaoncology
• LinkedInlinkedin.com/company/takedaoncology
• Instagraminstagram.com/TakedaOncology

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Takeda Oncology